Catalyst Event

Akeso Inc (9926) · Other

From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)

6/1/2026, 12:00:00 AM

OtherSentiment: Positive

Akeso announced that its drug Ivonescimab plus chemotherapy showed a 34% reduction in the risk of death in the Phase III HARMONi-6 trial for first-line advanced squamous non-small cell lung cancer. The landmark results were presented at the ASCO 2026 Plenary Session and published in The Lancet. High importance is estimated due to the significant clinical success in a major indication, likely resulting in >10% price impact scheduled.

Korean Translation

康方生物, 자사 약물 이보시맙(Ivonescimab)과 화학요법 병용이 1차 진행성 편평 비소세포폐암(sq-NSCLC) 대상 HARMONi-6 3상 임상시험에서 사망 위험을 34% 감소시켰다고 발표함. 이 획기적인 결과는 ASCO 2026 본회의에서 발표되었고 '더 랜싯(The Lancet)'에 게재됨. 주요 적응증에서의 유의미한 임상 성공으로 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline